Linked e-resources
Details
Table of Contents
Machine generated contents note: Part I: Evaluating HIV Prevention Programs: Context and Concepts
Chapter 1. Overview of HIV Prevention Programs in Developing Countries Michael H. Merson andJulia M. Dayton 13
Chapter 2. Implications of Economic Evaluations for National HIV Prevention Policy Makers David R. Holtgrave
and Steven D. Pinkerton 32
Chapter 3. Statistical Issues in HIV Prevention Ron Brookmeyer 55
Chapter 4. Epidemiological Issues in the Evaluation of HIV Prevention Programs Nancy S. Padian and Stephen C. Shiboski 79
Part II: Cost-Effectiveness and Resource Allocation
Chapter 5. Difficult Choices, Urgent Needs: Optimal Investment in HIV Prevention Programs Margaret L. Brandeau 97 Chapter 6. Methadone Treatment as HIV Prevention: Cost-EffectivenessAnalysis Harold Pollack 118
Chapter 7. Costs and Benefits of Imperfect HIV Vaccines: Implications for Vaccine Development and Use Douglas K Owens, Donna M. Edwards, and Ross D. Shachter 143
Part III: Case Studies
Chapter 8. Harm Reduction in Rome: A Model-Based Evaluation of Its Impact on the HIV-1 Epidemic MassimoArca, Teresa Spadea, Giulia Cesaroni, Marina Davoli, Annette D. Verster, and Carlo A. Perucci 175
Chapter 9. Evaluating Israel's Ethiopian Blood Ban EdwardH. Kaplan 189
Chapter 10. Feeding Strategies for Children of HIV-Infected Mothers: Modeling the Trade-Off Between HIV Infection and Non-HIV Mortality James G. Kahn, ElliotMarseille, and Joseph Saba 202
Part IV: New Methods for New Problems
Chapter 11. Design of HIVTrials for Estimating External Effects Tomas Philipson 223
Chapter 12. Estimation of Vaccine Efficacy for Prophylactic HIV Vaccines Ira M Longini, Jr., Michael G. Hudgens, and M. Elizabeth Halloran 241
Chapter 13. Health Policy Modeling: Epidemic Control, HIVVaccines, and
Risky Behavior Sally Blower, Katia Koelle,and John Mills 260
Chapter 14. Development and Validation of a Serologic Testing Algorithm for Recent HIV Seroconversion GlenA. Satten,
Robert S. Janssen, Susan Stramer, and Michael P Busch 290
Chapter 15. Issues in Quantitative Evaluation of Epidemiologic Evidence for Temporal Variability of HIV Infectivity Stephen C. Shiboski and Nancy S.
Padian 305.
Chapter 1. Overview of HIV Prevention Programs in Developing Countries Michael H. Merson andJulia M. Dayton 13
Chapter 2. Implications of Economic Evaluations for National HIV Prevention Policy Makers David R. Holtgrave
and Steven D. Pinkerton 32
Chapter 3. Statistical Issues in HIV Prevention Ron Brookmeyer 55
Chapter 4. Epidemiological Issues in the Evaluation of HIV Prevention Programs Nancy S. Padian and Stephen C. Shiboski 79
Part II: Cost-Effectiveness and Resource Allocation
Chapter 5. Difficult Choices, Urgent Needs: Optimal Investment in HIV Prevention Programs Margaret L. Brandeau 97 Chapter 6. Methadone Treatment as HIV Prevention: Cost-EffectivenessAnalysis Harold Pollack 118
Chapter 7. Costs and Benefits of Imperfect HIV Vaccines: Implications for Vaccine Development and Use Douglas K Owens, Donna M. Edwards, and Ross D. Shachter 143
Part III: Case Studies
Chapter 8. Harm Reduction in Rome: A Model-Based Evaluation of Its Impact on the HIV-1 Epidemic MassimoArca, Teresa Spadea, Giulia Cesaroni, Marina Davoli, Annette D. Verster, and Carlo A. Perucci 175
Chapter 9. Evaluating Israel's Ethiopian Blood Ban EdwardH. Kaplan 189
Chapter 10. Feeding Strategies for Children of HIV-Infected Mothers: Modeling the Trade-Off Between HIV Infection and Non-HIV Mortality James G. Kahn, ElliotMarseille, and Joseph Saba 202
Part IV: New Methods for New Problems
Chapter 11. Design of HIVTrials for Estimating External Effects Tomas Philipson 223
Chapter 12. Estimation of Vaccine Efficacy for Prophylactic HIV Vaccines Ira M Longini, Jr., Michael G. Hudgens, and M. Elizabeth Halloran 241
Chapter 13. Health Policy Modeling: Epidemic Control, HIVVaccines, and
Risky Behavior Sally Blower, Katia Koelle,and John Mills 260
Chapter 14. Development and Validation of a Serologic Testing Algorithm for Recent HIV Seroconversion GlenA. Satten,
Robert S. Janssen, Susan Stramer, and Michael P Busch 290
Chapter 15. Issues in Quantitative Evaluation of Epidemiologic Evidence for Temporal Variability of HIV Infectivity Stephen C. Shiboski and Nancy S.
Padian 305.